^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASD141

    i
    Other names: ASD141, Xi2396
    Associations

    News

    Trials
    Company:
    BRIM Biotech
    Drug class:
    CD11b inhibitor
    Associations

    News

    Trials
    2ms
    Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov)
    P1, N=21, Recruiting, Ascendo Biotechnology Co., Ltd. | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial primary completion date • First-in-human
    |
    ASD141
    over1year
    Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov)
    P1, N=21, Recruiting, Ascendo Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ASD141
    2years
    Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Ascendo Biotechnology Co., Ltd.
    New P1 trial
    |
    ASD141
    over4years
    ASD141, an innate checkpoint inhibitor, modulates tumor associated myeloid cells through CD11b and enhances current immune checkpoint blockade in preclinical model (SITC 2021)
    Our results showed that combination of Xi2396 and anti-PD1 synergistically suppressed tumor growth. Conclusions Altogether, our results provide support for clinical efforts to evaluate ASD141 as an innate immune checkpoint drug, especially in combination with commercial immune checkpoint inhibitors.
    Preclinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • ITGAM (Integrin, alpha M) • CD86 (CD86 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression • MHC-II expression
    |
    ASD141